Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.
News|Videos|September 23, 2026
An Uncharted Path: How Clinicians are Implementing Artificial Intelligence Across Cardiology
Fact checked by: Ryan Livingston
As AI continues to evolve at a breakneck pace, catch up on some of the ways it’s already been implemented in cardiovascular care.
Advertisement
Advertisement
Artificial intelligence (AI) is a burgeoning industry, evolving in practically every direction as it continues to develop. AI-based algorithms are being implemented in countless fields, medicine not least among them.
Related to this article
With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.
Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).
Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).
Adding spironolactone lowered 3-month home SBP by 7.7 mm Hg vs standard care in 160 stroke survivors with uncontrolled hypertension.
A systolic target below 120 mm Hg lowered major cardiovascular events vs below 140 mm Hg in 4368 patients with prior ischemic stroke or TIA.
Chronic hypertension in pregnancy was tied to 30% higher odds of critical congenital heart disease in a study of 44 million US births.
Ahmad Masri, MD, MS, highlights HCM agents to watch in 2027, including sotagliflozin and EDG-7500, and how MAPLE-HCM challenged beta-blocker use.
Advertisement
Advertisement